Form 4: ResMed CEO Michael Farrell Executes Stock Options and Sells Shares Under 10b5-1 Plan

ResMed's CEO, Michael J. Farrell, exercised stock options and sold a portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 7, 2025, Michael J. Farrell, the CEO of ResMed Inc., exercised options to acquire 8,009 shares of ResMed common stock at a price of $101.64 per share.
• Simultaneously, Farrell sold 8,009 shares of ResMed common stock at a weighted average price of $236.772, with individual sales prices ranging from $235.74 to $238.67.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024.
• Following these transactions, Farrell directly owns 455,472 shares of ResMed common stock.
• Farrell also indirectly owns 2,090 shares through the Lisette and Michael Farrell Family Trust and an unspecified amount through the Lisette and Michael Farrell Foundation.
• After the transaction, Farrell continues to hold 72,083 ResMed Common Stock Options.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, indicating a neutral sentiment. It doesn't suggest any immediate positive or negative implications for the company's performance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of Rule 10b5-1 plans allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information. Investors often monitor these transactions for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry often include stock options as a significant component.
• Companies like Medtronic, Stryker, and Boston Scientific also utilize stock options and similar equity-based compensation plans for their executives.
• The exercise and sale of shares by ResMed's CEO is a typical liquidity event for executives holding stock options.
• The use of a 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations, similar to practices employed by executives at comparable companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership structure.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

ResMed, Michael J. Farrell, stock options, Form 4, Rule 10b5-1, insider trading, executive compensation, share sale